Pfizer chooses Spain as gene therapy distribution centre for all of Europe
The American pharmaceutical company is to invest 70 million euros in the Madrid plant to increase its current production capacity
Pfizer has confirmed and reinforced its commitment to Spain and has chosen its biotechnology plant in San Sebastián de los Reyes (Madrid) to distribute its genetic therapies throughout Europe, aimed at advancing the treatment of rare diseases of genetic origin. The pharmaceutical company will in addition invest 70.2 million euros in this centre to increase its current production of drugs for haemophilia. "Pfizer has placed our country in a strategic position for both the company and science, helping to improve our sustainable economic development," explained the president and CEO of Pfizer in Spain, Sergio Rodríguez. With this investment, the plant will be equipped with the latest technology available and will provide the ability to continue producing essential drugs for many patients. “Pfizer's commitment to addressing rare diseases is very strong and these decisions are in line with this clear purpose. We have been investigating these diseases for more than 30 years, and more than 1 in 10 company innovations are aimed at patients who suffer from them”, he added. Rodríguez also recalled that this announcement is a "long-term commitment that represents an endorsement for the work carried out and for the quality of Pfizer's professionals in this country."
The production plant owned by Pfizer in San Sebastián de los Reyes (Madrid) is one of the company’s main biotechnology centres, as well as the only headquarters of the pharmaceutical company in the world that produces drugs for the treatment of two types of haemophilia, A and B, both rare diseases. With 300 professionals, it is mainly dedicated to the production and final packaging of highly complex, value added sterile lyophilized drugs; and it supplies more than 15,000 patients and 70 countries, including the United States, Japan and China, in addition to all European countries. As plant director Ana Maqueda explains, the main objective of the 70.2 million euro investment is "to prepare ourselves to grow, since we will have the capacity to produce new therapies while being ready to meet the expectations of industry regulators”.